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Reports 
 
 
 In cancer cells, monoallelic expression of oncogenes can 
occur through a variety of mechanisms including chromo-
somal translocation, alterations in promoter methylation, 
parental imprinting, and intrachromosomal deletion (1–3). 
A quintessential example is TAL1d, an 80-kb deletion on 
chromosome 1p33 that is found in 25% of cases of human T-
cell acute lymphoblastic leukemia (T-ALL). The deletion 
results in overexpression of TAL1, an oncogene coding for a 
basic helix-loop-helix transcription factor, by mediating fu-
sion of TAL1 coding sequences to the regulatory elements of 
the ubiquitously expressed gene “SCL-interrupting locus” 
(STIL) (4–6). However, we previously reported that a sub-
stantial proportion of T-ALLs, including the Jurkat T-ALL 
cell line, have monoallelic overexpression of TAL1 but lack 
either the TAL1d abnormality or a chromosomal transloca-
tion of the TAL1 locus (7, 8). 
We hypothesized that cis-
acting genomic lesions affecting 
TAL1 regulatory sequences might 
account for monoallelic TAL1 
activation. Chromatin immuno-
precipitation (ChIP) -seq analysis 
of Jurkat cells revealed aberrant 
histone H3 lysine 27 acetylation 
(H3K27ac), a mark of active 
transcription, starting upstream 
of the TAL1 transcriptional start 
site and extending across the 
first exons (Fig. 1A) (9, 10). Re-
gions with such rich and broad 
H3K27ac marks have been 
termed super-enhancers (also 
stretch enhancers or locus con-
trol regions) and are commonly 
found at genes that determine 
cell identity in embryonic stem 
(ES) cells, and in tumor cells at 
oncogenes critical for the malig-
nant cell state (11–17). The super-
enhancer encompassing TAL1 in 
Jurkat cells was aberrant, in that 
it was not present in fetal thy-
mocytes, normal CD34+ hema-
topoietic stem and progenitor 
cells (HSPCs) or in other T-ALL 
cell lines, such as TAL1d-positive 
RPMI-8402 cells and DND-41 T-
ALL cells that lack TAL1 expres-
sion (Fig. 1A) (9). Of note, chro-
matin conformation capture (3C) 
experiments recently performed 
in Jurkat cells identified a loop-
ing interaction involving an en-
hancer site 8 kb upstream of the 
transcription start site (TSS), 
which coincides with the loca-
tions of both the aberrant super-enhancer and the positive 
auto-regulatory binding sites for members of the TAL1 com-
plex in this cell line (Fig. 1A, red arrow) (9, 18). 
Sequencing of the genomic DNA region encompassing 
this site identified a heterozygous 12-bp insertion 
(GTTAGGAAACGG) that aligned precisely with the TAL1, 
GATA3, RUNX1, and HEB ChIP-seq peaks (Fig. 1B). Among 
eight additional TAL1-positive T-ALL cell lines, MOLT-3 
cells also harbored an abnormal heterozygous 2-bp insertion 
(GT) at the same site (Fig. 1B), while none of ten TAL1-
negative cell lines had a detectable genomic abnormality in 
this region (table S1). Among 146 unselected pediatric pri-
mary T-ALL samples collected at diagnosis, eight cases 
(5.5%) had heterozygous indels 2-18 bp in length that over-
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In certain human cancers, the expression of critical oncogenes is driven 
from large regulatory elements, called super-enhancers, which recruit 
much of the cell’s transcriptional apparatus and are defined by extensive 
acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute 
lymphoblastic leukemia (T-ALL) cases, we found that heterozygous 
somatic mutations are acquired that introduce binding motifs for the MYB 
transcription factor in a precise noncoding site, which creates a super-
enhancer upstream of the TAL1 oncogene. MYB binds to this new site and 
recruits its H3K27 acetylase binding partner CBP, as well as core 
components of a major leukemogenic transcriptional complex that contains 
RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-
enhancers found in T-ALL cells are occupied by MYB and CBP, suggesting a 
general role for MYB in super-enhancer initiation. Thus, this study 
identifies a genetic mechanism responsible for the generation of oncogenic 
super-enhancers in malignant cells. 
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lapped at the same clearly defined hotspot (indels at this 
site are referred to here as “mutation of the TAL1 enhancer,” 
MuTE) (Fig. 1B). We estimate that MuTE abnormalities ac-
count for about half of the cases with unexplained monoal-
lelic overexpression of TAL1 (7). Sequencing of DNA from 
remission bone marrow samples available from two muta-
tion-positive patients showed wild-type sequences at this 
site, indicating that the mutations were somatically ac-
quired in the tumor cells. All eight MuTE-positive T-ALLs 
markedly overexpressed TAL1 mRNA at levels comparable 
to those of the TAL1d-positive SUP-T13, and MuTE-positive 
Jurkat and MOLT-3 cells (Fig. 1C). Furthermore, MOLT-3 
cells, that share the same 2-bp insertion as patient 6, also 
had a super-enhancer at the TAL1 locus (Fig. 1A). 
To test our hypothesis that the aberrantly formed super-
enhancer drives monoallelic TAL1 expression, we analyzed 
the MuTE-positive samples for single nucleotide polymor-
phisms (SNPs) in the 3’ UTR of TAL1 gene from genomic 
DNA. Jurkat cells and five of the patient samples were in-
formative, and in each case only one allele was detectable in 
the RNA sample, indicating monoallelic expression of TAL1 
(fig. S1). We then used the UniPROBE database to analyze 
whether the mutant sequences introduced new transcrip-
tion factor binding sites (19). Surprisingly, all of the indels 
at this hotspot introduced de novo binding motifs for the 
MYB transcription factor, and two consecutive MYB binding 
motifs were generated by the 12-bp insertion in Jurkat cells 
(Fig. 2A and table S2). 
To ascertain if these mutations can activate gene expres-
sion, we cloned a 400-bp fragment containing either the 
wild-type allele or each of the TAL1-enhancer mutation al-
leles upstream of luciferase and tested the enhancer activity 
of this fragment in reporter assays. When we expressed 
these constructs in Jurkat cells, fragments containing each 
of the seven different indel mutations robustly increased 
reporter activity 3- to 14-fold more than the wild-type frag-
ment (Fig. 2B and fig. S2). Moreover, the activity of each of 
the mutant reporters was markedly reduced after MYB 
knockdown, indicating that the enhancer activity imparted 
by the mutations was indeed mediated by MYB (Fig. 2B). 
When we performed these experiments in HEK-293T cells, 
the mutant reporters had no increased activity above that of 
the wild-type reporter (fig. S2), suggesting that transcription 
factors expressed in T-ALL, such as members of the TAL1 
complex, are involved in activation of the mutant enhancer. 
We conclude that in T-ALL primary samples and cell lines, 
indel mutations that introduce MYB binding sites at a 
hotspot 7.5 kb upstream from the TSS of TAL1 generate a 
super-enhancer that drives monallelic overexpression of this 
oncogene. 
Our recent ChIP-seq studies of the TAL1 complex in T-
ALL cells identified binding of transcription factors in the 
core TAL1 complex (TAL1, GATA3, RUNX1, E2A and HEB) 
at the MYB enhancer, while knockdown of MYB generated a 
gene expression signature closely related to TAL1 knock-
down (9, 10). We were technically unable to analyze MYB 
binding by ChIP-seq in our previous study, so at that time 
we interpreted these results to indicate that MYB is a criti-
cal downstream hub of the TAL1 complex (10). However, in 
the current study we used newly available MYB-specific an-
tibodies to generate high-resolution maps of genome-wide 
MYB binding in Jurkat cells. Analysis of the TAL1 enhancer 
indel mutation site in Jurkat cells showed precise alignment 
of MYB binding and binding of each member of the TAL1 
complex (Fig. 3A). There was also an abundance of RNA 
polymerase II (Pol II) and Mediator (MED1), stretching over 
more than 20 kb, indicating a large super-enhancer (table 
S3) (15). Notably, this site is also bound by MYB and TAL1 in 
MuTE-positive MOLT-3 cells (Fig. 3A), but not in RPMI-
8402 and CCRF-CEM cells or a primary T-ALL sample, each 
of which overexpresses TAL1 driven by TAL1d (fig. S3). Nor 
were we able to detect binding of TAL1 at this site in HSPCs 
(fig. S3), indicating that a small insertion creating a de novo 
MYB binding motif at this location is required for MYB 
binding and subsequent binding by other members of the 
TAL1 complex. Accordingly, knockdown of MYB resulted in 
depletion of TAL1 expression in both Jurkat and MOLT-3 
cells (fig. S4). Thus, MYB binding to the MuTE hotspot in a 
subset of TAL1-overexpressing T-ALLs results in the accu-
mulation of an abundance of H3K27ac marks and aberrantly 
nucleates binding by other members of the TAL1 complex, 
leading to aberrant upregulation of TAL1 gene expression. 
We next asked why the mutations we had identified in 
primary patient T-ALLs were clustered in a defined genomic 
location. A search for predicted transcription factor binding 
sites near the MuTE site identified the preferred binding 
sequences for RUNX1, GATA3, and ETS1, as well as E-box 
motifs characteristic of binding by TAL1/E-protein hetero-
dimers (fig. S5). The absence of predicted MYB binding sites 
suggests that the MuTE is critical for MYB binding, and 
supports our hypothesis that MYB binding to its de novo 
motif is crucial to binding by members of the TAL1 complex 
at this hotspot. To explore this concept further, we extracted 
the raw ChIP-seq reads and determined the allelic frequency 
of mutant to wild-type reads of bound DNA fragments at the 
mutation site. Strikingly, in MOLT-3 cells, both MYB and 
TAL1 bound predominantly to the mutant allele, with 67 of 
the 68 reads, and 37 of 38 reads, revealing the mutant se-
quence in the bound DNA. Likewise, in Jurkat cells, 404 of 
419 reads, and 12 of 14 reads, contained the mutant se-
quence from MYB and TAL1 ChIP, indicating that these 
transcription factors predominantly bind monoallelically to 
the mutant allele. Thus, our data indicate that indels pro-
ducing MYB binding sites occur at a defined genomic loca-
tion, probably because they must be in proximity to binding 
sites for other members of the TAL1 complex. 
Given the well-established direct interaction between 
MYB and its potent transcriptional coactivator, CREB-
binding protein (CBP) (20), we also analyzed ChIP-seq 
tracks for CBP in Jurkat cells, discovering that CBP was also 
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present at the TAL1 enhancer indel mutation site (Fig. 3A). 
Because CBP promotes H3K27 acetylation and antagonizes 
Polycomb silencing (21), it seems likely that the initial event 
in the aberrant super-enhancer formation at this site is the 
recruitment of CBP by MYB, resulting in abundant H3K27 
acetylation that opens the chromatin and permits binding 
by the other members of the TAL1 complex. 
In a sense the mutations forming MYB binding sites up-
stream of the TAL1 gene in T-ALLs represent an “experi-
ment of nature” that reveals the capacity of MYB binding to 
aberrantly nucleate a large super-enhancer that drives high 
levels of expression of a gene critical for the leukemic cell 
state. Thus, we interrogated the normal binding sites of 
MYB and we observed highly concordant binding of MYB 
with members of the TAL1 complex throughout the genome 
(Fig. 3B), in that 80% of TAL1 binding sites were also co-
occupied by MYB. We were also able to demonstrate a 
strong association of TAL1 and MYB proteins biochemically 
in reciprocal co-immunoprecipitation experiments (Fig. 3C). 
Next we focused on the positive interconnected auto-
regulatory loop that we had identified previously, whereby 
the core components of the complex, TAL1, GATA3, and 
RUNX1, positively regulate their own enhancers (9). We 
found MYB bound with TAL1, GATA3, and RUNX1 at each 
of their respective enhancers, including one within the MYB 
gene itself (fig. S6). Notably, the TAL1 complex binding sites 
associated with all four of these genes also contained large 
super-enhancer domains, and all showed CBP-MYB co-
occupancy. Furthermore, siRNA knockdown of MYB was 
sufficient to deplete TAL1, GATA3, and RUNX1 (fig. S6). 
Thus, MYB is not only a core component of the TAL1 com-
plex, but also a key factor involved in initiating the autoreg-
ulatory positive-feedback circuitry (fig. S6). 
To demonstrate definitively that MuTEs are responsible 
for TAL1 overexpression in a subset of T-ALL patients, we 
employed CRISPR/Cas9 technology to disrupt the MuTE site 
in Jurkat cells. Initially, we had difficulty expanding single 
cell clones with deletion of the MuTE site, suggesting that 
deletion of the mutated enhancer site was diminishing TAL1 
levels to a degree that impaired cell survival. Thus, we engi-
neered Jurkat cells to express TAL1 cDNA lacking the 3’ 
UTR from a retroviral vector, and performed all of our 
CRISPR/Cas9 experiments in these cells. 
To directly target the enhancer mutation site in Jurkat 
cells, we first generated clones with a deletion of approxi-
mately 180 bp by targeting two guide RNAs to sites flanking 
either side of the enhancer mutation. Clones expanded from 
single cells harbored genomic deletions of 177-193 bp that 
involved either the wild-type allele or mutant allele, or both 
alleles (Fig. 4A and fig. S7). Deletion of the wild-type allele 
had no effect on endogenous TAL1 mRNA levels, but dele-
tion of the mutant allele completely abrogated endogenous 
TAL1 expression, indicating that the enhancer mutation is 
responsible for TAL1 overexpression in these cells. Further-
more, ChIP-seq for H3K27ac showed complete collapse of 
the super-enhancer at the TAL1 locus when the deletion af-
fected the allele with the enhancer mutation, but was not 
affected when the deletion involved only the wild-type allele 
(Fig. 4B, fig. S8 and fig. S9). 
We also targeted a single guide RNA to specific sequenc-
es that form part of the 12-bp insertion in Jurkat cells, per-
mitting us to propagate single cell clones with a spectrum of 
repair-induced indel mutations directly at the insertion site 
(Fig. 4C). In clones with deletion of 6 bp of the 12-bp en-
hancer insertion, encompassing one of the two inserted 
MYB binding sites, endogenous TAL1 expression levels de-
creased by approximately 60%, while clones with more ex-
tensive deletions had endogenous TAL1 expression levels 
decreased by approximately 85% (Fig 4C). Thus, the MuTE 
is clearly responsible for TAL1 overexpression in Jurkat 
cells. 
Importantly, our ChIP-seq results also show that MYB 
and CBP were bound together at 727 of the 818 (89%) super-
enhancer regions that are present in Jurkat cells. When we 
performed shRNA knockdown for MYB, 221 of 818 (27%) 
super-enhancer associated genes decreased significantly in 
expression (9, 17), suggesting MYB has an active role in reg-
ulating their transcription. These results are consistent with 
the interpretation that MYB-CBP binding and the subse-
quent formation of abundant H3K27 acetylation marks may 
be broadly involved in the formation of super-enhancers in 
T-ALL. Thus, the role that we have shown for MYB binding 
in super-enhancer formation in a subset of T-ALLs with 
strategically placed somatic indel mutations in all likelihood 
provides insight into the general question of how super-
enhancers are formed at the site of genes critical for the 
establishment of the T-ALL cell state. MYB is known to 
function as a master regulator of early and adult hemato-
poiesis, and to undergo transcriptional downregulation after 
lineage commitment and differentiation (22). An interesting 
area for future study will be to determine whether MYB acts 
in concert with CBP to regulate super-enhancer formation 
at genes critical for defining cell identity during normal 
hematopoietic cell differentiation (14, 16, 23, 24). 
Our findings show that somatic mutation of noncoding 
intergenic elements can lead to binding of master transcrip-
tion factors, such as MYB, which in turn aberrantly initiate 
super-enhancers that mediate overexpression of oncogenes. 
This raises the possibility that acquisition of such enhancer 
mutations may constitute a general mechanism of carcino-
genesis employed in other types of human cancers. Mecha-
nisms of aberrant super-enhancer formation in malignancy 
have broad implications not only for molecular pathogene-
sis, but also for clinical management. Drugs that target key 
components of the transcriptional machinery, such as BRD4 
and CDK7 (12, 13, 17), have recently been shown to preferen-
tially target tumor-specific super-enhancers, which provides 
a novel strategy to capitalize on these abnormalities for im-
proved cancer therapy. 
 
/ sciencemag.org/content/early/recent / 13 November 2014 / Page 3 / 10.1126/science.1259037 
 
REFERENCES AND NOTES 
1. E. J. Walker, C. Zhang, P. Castelo-Branco, C. Hawkins, W. Wilson, N. Zhukova, N. 
Alon, A. Novokmet, B. Baskin, P. Ray, C. Knobbe, P. Dirks, M. D. Taylor, S. Croul, 
D. Malkin, U. Tabori, Monoallelic expression determines oncogenic progression 
and outcome in benign and malignant brain tumors. Cancer Res. 72, 636–644 
(2012). Medline doi:10.1158/0008-5472.CAN-11-2266 
2. A. Gimelbrant, J. N. Hutchinson, B. R. Thompson, A. Chess, Widespread 
monoallelic expression on human autosomes. Science 318, 1136–1140 (2007). 
Medline doi:10.1126/science.1148910 
3. R. L. Jirtle, Genomic imprinting and cancer. Exp. Cell Res. 248, 18–24 (1999). 
Medline doi:10.1006/excr.1999.4453 
4. T. M. Breit, E. J. Mol, I. L. Wolvers-Tettero, W. D. Ludwig, E. R. van Wering, J. J. van 
Dongen, Site-specific deletions involving the tal-1 and sil genes are restricted to 
cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion 
mechanism affects multiple genes. J. Exp. Med. 177, 965–977 (1993). Medline 
doi:10.1084/jem.177.4.965 
5. L. Brown, J. T. Cheng, Q. Chen, M. J. Siciliano, W. Crist, G. Buchanan, R. Baer, Site-
specific recombination of the tal-1 gene is a common occurrence in human T cell 
leukemia. EMBO J. 9, 3343–3351 (1990). Medline 
6. P. D. Aplan, D. P. Lombardi, A. M. Ginsberg, J. Cossman, V. L. Bertness, I. R. 
Kirsch, Disruption of the human SCL locus by “illegitimate” V-(D)-J recombinase 
activity. Science 250, 1426–1429 (1990). Medline doi:10.1126/science.2255914 
7. A. A. Ferrando, S. Herblot, T. Palomero, M. Hansen, T. Hoang, E. A. Fox, A. T. Look, 
Biallelic transcriptional activation of oncogenic transcription factors in T-cell 
acute lymphoblastic leukemia. Blood 103, 1909–1911 (2004). Medline 
doi:10.1182/blood-2003-07-2577 
8. K. Leroy-Viard, M. A. Vinit, N. Lecointe, D. Mathieu-Mahul, P. H. Roméo, Distinct 
DNase-I hypersensitive sites are associated with TAL-1 transcription in erythroid 
and T-cell lines. Blood 84, 3819–3827 (1994). Medline 
9. T. Sanda, L. N. Lawton, M. I. Barrasa, Z. P. Fan, H. Kohlhammer, A. Gutierrez, W. 
Ma, J. Tatarek, Y. Ahn, M. A. Kelliher, C. H. Jamieson, L. M. Staudt, R. A. Young, A. 
T. Look, Core transcriptional regulatory circuit controlled by the TAL1 complex in 
human T cell acute lymphoblastic leukemia. Cancer Cell 22, 209–221 (2012). 
Medline doi:10.1016/j.ccr.2012.06.007 
10. M. R. Mansour, T. Sanda, L. N. Lawton, X. Li, T. Kreslavsky, C. D. Novina, M. 
Brand, A. Gutierrez, M. A. Kelliher, C. H. Jamieson, H. von Boehmer, R. A. Young, 
A. T. Look, The TAL1 complex targets the FBXW7 tumor suppressor by activating 
miR-223 in human T cell acute lymphoblastic leukemia. J. Exp. Med. 210, 1545–
1557 (2013). Medline doi:10.1084/jem.20122516 
11. R. Siersbæk, A. Rabiee, R. Nielsen, S. Sidoli, S. Traynor, A. Loft, L. L. C. Poulsen, A. 
Rogowska-Wrzesinska, O. N. Jensen, S. Mandrup, Transcription factor 
cooperativity in early adipogenic hotspots and super-enhancers. Cell Rep. 7, 
1443–1455 (2014). doi:10.1016/j.celrep.2014.04.042 
12. J. Lovén, H. A. Hoke, C. Y. Lin, A. Lau, D. A. Orlando, C. R. Vakoc, J. E. Bradner, T. 
I. Lee, R. A. Young, Selective inhibition of tumor oncogenes by disruption of 
super-enhancers. Cell 153, 320–334 (2013). Medline 
doi:10.1016/j.cell.2013.03.036 
13. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, 
T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. 
Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La 
Thangue, C. A. French, O. Wiest, A. L. Kung, S. Knapp, J. E. Bradner, Selective 
inhibition of BET bromodomains. Nature 468, 1067–1073 (2010). Medline 
doi:10.1038/nature09504 
14. S. C. Parker, M. L. Stitzel, D. L. Taylor, J. M. Orozco, M. R. Erdos, J. A. Akiyama, K. 
L. van Bueren, P. S. Chines, N. Narisu, B. L. Black, A. Visel, L. A. Pennacchio, F. S. 
Collins, J. Becker, B. Benjamin, R. Blakesley, G. Bouffard, S. Brooks, H. Coleman, 
M. Dekhtyar, M. Gregory, X. Guan, J. Gupta, J. Han, A. Hargrove, S. Ho, T. 
Johnson, R. Legaspi, S. Lovett, Q. Maduro, C. Masiello, B. Maskeri, J. McDowell, 
C. Montemayor, J. Mullikin, M. Park, N. Riebow, K. Schandler, B. Schmidt, C. 
Sison, M. Stantripop, J. Thomas, P. Thomas, M. Vemulapalli, A. Young; NISC 
Comparative Sequencing Program; National Institutes of Health Intramural 
Sequencing Center Comparative Sequencing Program Authors; NISC 
Comparative Sequencing Program Authors, Chromatin stretch enhancer states 
drive cell-specific gene regulation and harbor human disease risk variants. Proc. 
Natl. Acad. Sci. U.S.A. 110, 17921–17926 (2013). Medline 
doi:10.1073/pnas.1317023110 
15. D. Hnisz, B. J. Abraham, T. I. Lee, A. Lau, V. Saint-André, A. A. Sigova, H. A. Hoke, 
R. A. Young, Super-enhancers in the control of cell identity and disease. Cell 155, 
934–947 (2013). Medline doi:10.1016/j.cell.2013.09.053 
16. W. A. Whyte, D. A. Orlando, D. Hnisz, B. J. Abraham, C. Y. Lin, M. H. Kagey, P. B. 
Rahl, T. I. Lee, R. A. Young, Master transcription factors and mediator establish 
super-enhancers at key cell identity genes. Cell 153, 307–319 (2013). Medline 
doi:10.1016/j.cell.2013.03.035 
17. N. Kwiatkowski, T. Zhang, P. B. Rahl, B. J. Abraham, J. Reddy, S. B. Ficarro, A. 
Dastur, A. Amzallag, S. Ramaswamy, B. Tesar, C. E. Jenkins, N. M. Hannett, D. 
McMillin, T. Sanda, T. Sim, N. D. Kim, T. Look, C. S. Mitsiades, A. P. Weng, J. R. 
Brown, C. H. Benes, J. A. Marto, R. A. Young, N. S. Gray, Targeting transcription 
regulation in cancer with a covalent CDK7 inhibitor. Nature 511, 616–620 (2014). 
Medline doi:10.1038/nature13393 
18. Y. Zhou, S. Kurukuti, P. Saffrey, M. Vukovic, A. M. Michie, R. Strogantsev, A. G. 
West, D. Vetrie, Chromatin looping defines expression of TAL1, its flanking genes, 
and regulation in T-ALL. Blood 122, 4199–4209 (2013). Medline 
doi:10.1182/blood-2013-02-483875 
19. D. E. Newburger, M. L. Bulyk, UniPROBE: An online database of protein binding 
microarray data on protein-DNA interactions. Nucleic Acids Res. 37 (Database), 
D77–D82 (2009). Medline doi:10.1093/nar/gkn660 
20. P. Dai, H. Akimaru, Y. Tanaka, D. X. Hou, T. Yasukawa, C. Kanei-Ishii, T. 
Takahashi, S. Ishii, CBP as a transcriptional coactivator of c-Myb. Genes Dev. 10, 
528–540 (1996). Medline doi:10.1101/gad.10.5.528 
21. F. Tie, R. Banerjee, A. R. Saiakhova, B. Howard, K. E. Monteith, P. C. Scacheri, M. 
S. Cosgrove, P. J. Harte, Trithorax monomethylates histone H3K4 and interacts 
directly with CBP to promote H3K27 acetylation and antagonize Polycomb 
silencing. Development 141, 1129–1139 (2014). Medline doi:10.1242/dev.102392 
22. C. Schulz, E. G. Perdiguero, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, 
M. Prinz, B. Wu, S. E. W. Jacobsen, J. W. Pollard, J. Frampton, K. J. Liu, F. 
Geissmann, A lineage of myeloid cells independent of Myb and hematopoietic 
stem cells. Science 336, 86–90 (2012). Medline doi:10.1126/science.1219179 
23. A. Rada-Iglesias, R. Bajpai, T. Swigut, S. A. Brugmann, R. A. Flynn, J. Wysocka, A 
unique chromatin signature uncovers early developmental enhancers in humans. 
Nature 470, 279–283 (2011). Medline doi:10.1038/nature09692 
24. M. P. Creyghton, A. W. Cheng, G. G. Welstead, T. Kooistra, B. W. Carey, E. J. 
Steine, J. Hanna, M. A. Lodato, G. M. Frampton, P. A. Sharp, L. A. Boyer, R. A. 
Young, R. Jaenisch, Histone H3K27ac separates active from poised enhancers 
and predicts developmental state. Proc. Natl. Acad. Sci. U.S.A. 107, 21931–21936 
(2010). Medline doi:10.1073/pnas.1016071107 
25. A. Gutierrez, T. Sanda, W. Ma, J. Zhang, R. Grebliunaite, S. Dahlberg, D. Neuberg, 
A. Protopopov, S. S. Winter, R. S. Larson, M. J. Borowitz, L. B. Silverman, L. Chin, 
S. P. Hunger, C. Jamieson, S. E. Sallan, A. T. Look, Inactivation of LEF1 in T-cell 
acute lymphoblastic leukemia. Blood 115, 2845–2851 (2010). Medline 
doi:10.1182/blood-2009-07-234377 
26. A. Gutierrez, S. E. Dahlberg, D. S. Neuberg, J. Zhang, R. Grebliunaite, T. Sanda, A. 
Protopopov, V. Tosello, J. Kutok, R. S. Larson, M. J. Borowitz, M. L. Loh, A. A. 
Ferrando, S. S. Winter, C. G. Mullighan, L. B. Silverman, L. Chin, S. P. Hunger, S. 
E. Sallan, A. T. Look, Absence of biallelic TCRgamma deletion predicts early 
treatment failure in pediatric T-cell acute lymphoblastic leukemia. J. Clin. Oncol. 
28, 3816–3823 (2010). Medline doi:10.1200/JCO.2010.28.3390 
27. A. Gutierrez, T. Sanda, R. Grebliunaite, A. Carracedo, L. Salmena, Y. Ahn, S. 
Dahlberg, D. Neuberg, L. A. Moreau, S. S. Winter, R. Larson, J. Zhang, A. 
Protopopov, L. Chin, P. P. Pandolfi, L. B. Silverman, S. P. Hunger, S. E. Sallan, A. 
T. Look, High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute 
lymphoblastic leukemia. Blood 114, 647–650 (2009). Medline 
doi:10.1182/blood-2009-02-206722 
28. A. A. Ferrando, D. S. Neuberg, J. Staunton, M. L. Loh, C. Huard, S. C. Raimondi, F. 
G. Behm, C. H. Pui, J. R. Downing, D. G. Gilliland, E. S. Lander, T. R. Golub, A. T. 
Look, Gene expression signatures define novel oncogenic pathways in T cell 
acute lymphoblastic leukemia. Cancer Cell 1, 75–87 (2002). Medline 
doi:10.1016/S1535-6108(02)00018-1 
29. I. Lahortiga, K. De Keersmaecker, P. Van Vlierberghe, C. Graux, B. Cauwelier, F. 
Lambert, N. Mentens, H. B. Beverloo, R. Pieters, F. Speleman, M. D. Odero, M. 
Bauters, G. Froyen, P. Marynen, P. Vandenberghe, I. Wlodarska, J. P. Meijerink, J. 
Cools, Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. 
Nat. Genet. 39, 593–595 (2007). Medline doi:10.1038/ng2025 
30. S. Jin, H. Zhao, Y. Yi, Y. Nakata, A. Kalota, A. M. Gewirtz, c-Myb binds MLL 
through menin in human leukemia cells and is an important driver of MLL-
associated leukemogenesis. J. Clin. Invest. 120, 593–606 (2010). Medline 
doi:10.1172/JCI38030 
/ sciencemag.org/content/early/recent / 13 November 2014 / Page 4 / 10.1126/science.1259037 
 
31. A. Marson, S. S. Levine, M. F. Cole, G. M. Frampton, T. Brambrink, S. Johnstone, 
M. G. Guenther, W. K. Johnston, M. Wernig, J. Newman, J. M. Calabrese, L. M. 
Dennis, T. L. Volkert, S. Gupta, J. Love, N. Hannett, P. A. Sharp, D. P. Bartel, R. 
Jaenisch, R. A. Young, Connecting microRNA genes to the core transcriptional 
regulatory circuitry of embryonic stem cells. Cell 134, 521–533 (2008). Medline 
doi:10.1016/j.cell.2008.07.020 
32. T. I. Lee, S. E. Johnstone, R. A. Young, Chromatin immunoprecipitation and 
microarray-based analysis of protein location. Nat. Protoc. 1, 729–748 (2006). 
Medline doi:10.1038/nprot.2006.98 
33. B. Langmead, C. Trapnell, M. Pop, S. L. Salzberg, Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 
(2009). Medline doi:10.1186/gb-2009-10-3-r25 
34. W. J. Kent, C. W. Sugnet, T. S. Furey, K. M. Roskin, T. H. Pringle, A. M. Zahler, D. 
Haussler, The human genome browser at UCSC. Genome Res. 12, 996–1006 
(2002). Medline doi:10.1101/gr.229102. Article published online before print in 
May 2002 
35. Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoute, D. S. Johnson, B. E. Bernstein, C. 
Nusbaum, R. M. Myers, M. Brown, W. Li, X. S. Liu, Model-based analysis of ChIP-
Seq (MACS). Genome Biol. 9, R137 (2008). Medline doi:10.1186/gb-2008-9-9-
r137 
36. V. Matys, O. V. Kel-Margoulis, E. Fricke, I. Liebich, S. Land, A. Barre-Dirrie, I. 
Reuter, D. Chekmenev, M. Krull, K. Hornischer, N. Voss, P. Stegmaier, B. Lewicki-
Potapov, H. Saxel, A. E. Kel, E. Wingender, TRANSFAC and its module 
TRANSCompel: Transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 
34, D108–D110 (2006). Medline doi:10.1093/nar/gkj143 
37. I. V. Kulakovskiy, Y. A. Medvedeva, U. Schaefer, A. S. Kasianov, I. E. Vorontsov, V. 
B. Bajic, V. J. Makeev, HOCOMOCO: A comprehensive collection of human 
transcription factor binding sites models. Nucleic Acids Res. 41 (D1), D195–D202 
(2013). Medline doi:10.1093/nar/gks1089 
38. C. E. Grant, T. L. Bailey, W. S. Noble, FIMO: Scanning for occurrences of a given 
motif. Bioinformatics 27, 1017–1018 (2011). Medline 
doi:10.1093/bioinformatics/btr064 
39. P. D. Hsu, D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, 
E. J. Fine, X. Wu, O. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao, F. Zhang, DNA 
targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–
832 (2013). Medline doi:10.1038/nbt.2647 
40. M. C. Canver, D. E. Bauer, A. Dass, Y. Y. Yien, J. Chung, T. Masuda, T. Maeda, B. 
H. Paw, S. H. Orkin, Characterization of genomic deletion efficiency mediated by 
clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease 
system in mammalian cells. J. Biol. Chem. 289, 21312–21324 (2014). Medline 
doi:10.1074/jbc.M114.564625 
41. L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, 
L. A. Marraffini, F. Zhang, Multiplex genome engineering using CRISPR/Cas 
systems. Science 339, 819–823 (2013). Medline doi:10.1126/science.1231143 
42. F. A. Ran, P. D. Hsu, J. Wright, V. Agarwala, D. A. Scott, F. Zhang, Genome 
engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013). 
Medline doi:10.1038/nprot.2013.143 
43. C. G. Palii, C. Perez-Iratxeta, Z. Yao, Y. Cao, F. Dai, J. Davison, H. Atkins, D. Allan, 
F. J. Dilworth, R. Gentleman, S. J. Tapscott, M. Brand, Differential genomic 
targeting of the transcription factor TAL1 in alternate haematopoietic lineages. 
EMBO J. 30, 494–509 (2011). Medline doi:10.1038/emboj.2010.342 
44. O. Bernard, P. Guglielmi, P. Jonveaux, D. Cherif, S. Gisselbrecht, M. Mauchauffe, 
R. Berger, C. J. Larsen, D. Mathieu-Mahul, Two distinct mechanisms for the SCL 
gene activation in the t(1;14) translocation of T-cell leukemias. Genes 
Chromosomes Cancer 1, 194–208 (1990). Medline 
doi:10.1002/gcc.2870010303 
ACKNOWLEDGMENTS 
We thank J. Gilbert for helpful editorial comments on the manuscript, and F.Alt and 
F. Meng for helpful advice on the design of the CRISPR experiments. We 
gratefully acknowledge the children with T-ALL and their families for the samples 
analyzed in these studies. M.R.M. was supported by the Claudia Adams Barr 
Innovative Basic Science Research Program, the Kay Kendall Leukaemia Trust, 
and a Bennett Fellowship from Leukaemia and Lymphoma Research, UK. A.G. is 
a Research Fellow of the Gabrielle’s Angel Foundation for Cancer Research, a 
Clinical Investigator of the Damon Runyon Cancer Research Foundation, and is 
supported by grants National Cancer Institute, NIH, CA167124, Department of 
Defense CA120215 and an award from the William Lawrence & Blanche Hughes 
Foundation. T.S. is supported by a grant from the National Research Foundation 
(NRF), Prime Minister’s Office, Singapore under its NRF Fellowship Program 
(award no. NRF-NRFF2013-02). This work was funded by National Institute of 
Health grants 1R01CA176746-01 and 5P01CA109901-08 (A.T.L.), and 
5P01CA68484 (S.E.S. and A.T.L.). Children's Oncology Group cell banking and 
sample distribution were supported by grants CA98543, CA114766, CA98413, 
CA30969, and CA29139 from the National Institutes of Health. S.P.H. is the 
Ergen Family Chair in Pediatric Cancer. R.A.Y. is a founder and member of the 
Board of Directors of Syros Pharmaceuticals, a company developing therapies 
that target gene regulatory elements including super-enhancers. 
SUPPLEMENTARY MATERIALS 
www.sciencemag.org/cgi/content/full/science.1259037/DC1 
Materials and Methods 
Figs. S1 to S9 
Tables S1 to S3 
References (25–44) 
 
22 July 2014; accepted 04 November 2014 
Published online 13 November 2014 
10.1126/science.1259037 
 
/ sciencemag.org/content/early/recent / 13 November 2014 / Page 5 / 10.1126/science.1259037 
 
  
Figure 1. Mutations at an 
intergenic site are associated 
with the TAL1 super-enhancer in 
T-ALL cells (A) Normalized ChIP-
seq tracks for H3K27ac at the 
STIL-TAL1 locus in two human 
purified normal hematopoietic 
stem cell samples (CD34), the 
RPMI-8402 T-ALL cell line that 
over-expresses TAL1 as a result of 
TAL1d, DND-41 T-ALL cells that do 
not express TAL1, human fetal 
thymic tissue, and MOLT-3 and 
Jurkat cells that have mutations at 
a non-coding site 7.5 kb from the 
TAL1 transcriptional start site (red 
arrow). ChIP-seq read densities 
(y-axis) were normalized to reads 
per million reads sequenced in 
each sample. (B) Sequence 
alignments of the -7.5 kb site 
showing wild-type (WT) 
sequences in black and inserted 
sequences in red for Jurkat and 
MOLT-3 T-ALL cell lines and eight 
pediatric T-ALL patients. (C) TAL1 
mRNA expression as determined 
by quantitative PCR and 
expressed as percentage of 
GAPDH. Error bars are ±SEM from 
two independent experiments 
performed in triplicate. 
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Fig. 2. Mutations of the TAL1 
enhancer activate through 
recruitment of MYB. (A) All 
TAL1 enhancer mutations 
introduce de novo MYB binding 
sites as determined by 
UniPROBE (19). The MYB 
primary binding motif is shown 
above the mutation-derived 
MYB motifs, with inserted 
nucleotides shown in red. (B) A 
400 bp fragment of the -7.5 kb 
TAL1 enhancer containing either 
the wild-type sequence or each 
of the mutant alleles was cloned 
upstream of luciferase and a 
minimal promoter. Constructs 
were nucleofected into Jurkat 
cells, together with either 
control siRNA, or two 
independent siRNAs targeting 
MYB. Firefly luciferase activity 
was measured at 24 hrs, 
normalized to renilla luciferase 
to control for cell number and 
transfection efficiency, and 
expressed as a ratio relative to 
activity of the wild-type STIL-
TAL enhancer construct. Error 
bars are ±SEM from two 
independent experiments 
performed in triplicate. 
Corresponding immunoblots for 
MYB and tubulin are shown 
below. 
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Fig. 3. MYB binds the 
mutant TAL1 enhancer site 
and is a member of the TAL1 
complex. (A) ChIP-seq tracks 
at the STIL-TAL1 locus from 
Jurkat and MOLT-3 T-ALL 
cells for GATA3, HEB, RUNX1, 
TAL1, CBP, MYB (ab45150 
antibody), MYB (05-175 
antibody), RNA polymerase II 
(Pol II), and Mediator 1 
(MED1). The mutation site at -
7.5 kb is depicted with a red 
arrow. ChIP-seq read 
densities (y-axis) were 
normalized to reads per 
million reads sequenced in 
each sample. (B) Heatmaps 
showing genome-wide co-
occupancy of MYB binding 
sites (+/- 1 kb) with those 
from TAL1, RUNX1, GATA3, 
and CBP sites as determined 
by ChIP-seq. For each region 
(y axis), the sequence density 
centered at 0 indicates 
overlapping bound regions. 
(C) Co-immunoprecipitation 
(Co-IP) and reciprocal Co-IP 
experiments performed from 
Jurkat lysates for MYB and 
TAL1. WCL, whole cell lysate; 
IgG, isotype control IgG 
antibody. 
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 Fig. 4. Targeted deletion of the TAL1 enhancer mutation collapses the 
TAL1 super-enhancer. (A) Targeted deletion of 177-193 bp of the mutant but 
not wild-type allele in Jurkat cells abrogates expression of endogenous TAL1, 
as determined by qRT-PCR. Data are mean ± SD of two independent 
experiments performed in triplicate. Agarose gel of products from PCR 
amplification across the MuTE site for CRISPR/Cas9 Jurkat clones. All 
clones, including parental cells, express MSCV-TAL1. Hyperladder IV on right. 
Genotype for each clone is shown below: +, allele present; Δ, deleted allele. 
(B) ChIP-seq tracks for H3K27ac and MYB at the STIL-TAL1 locus from 
selected CRISPR/Cas9 clones. ChIP-seq read densities (y-axis) were 
normalized to reads per million reads sequenced in each sample. (C) 
Sequence alignments of Jurkat clones targeted by CRISPR/Cas9 gsRNA#3 
(target sequence is highlighted in grey, PAM sequence in yellow), which 
targets the 12 bp insertion in Jurkat cells (red font), but not the wild-type 
allele. Endogenous TAL1 expression as determined by qRT-PCR for 
respective clones are shown. Data are mean ± SD of two independent 
experiments performed in triplicate. 
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